Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE
A phase 3 trial of 177Lu-edotreotide, Temozolomide, Capecitabine, Everolimus, Leucovorin (folinic acid) and Oxaliplatin in neuroendocrine tumours, run by ITM Solucin GmbH, active and no longer recruiting.
Overview
Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE is a phase 3 interventional study registered as NCT04919226 by ITM Solucin GmbH, with 259 participants enrolled, started 2021-12-21 and due to reach its primary completion in 2027-06. Interventions recorded: 177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT, CAPTEM (Capecitabine and Temozolomide), Everolimus and FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin).
Similar pages
not linked directly; found by shared links- TrialEvaluation of the Preliminary Efficacy and Safety of DR30206 in Combination With Standard Therapy in Patients With Gastrointestinal Cancer
Shares Leucovorin (folinic acid), Oxaliplatin, Capecitabine and the tag pipeline.
- TrialA Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
Shares Leucovorin (folinic acid), Oxaliplatin, Capecitabine and the tag pipeline.
- TrialIrinotecan Hydrochloride Liposome Injection (II)in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Metastatic Pancreatic Cancer
Shares Leucovorin (folinic acid), Oxaliplatin and the tag pipeline.
- TrialA Phase Ib/II Trial of HS-20110 Combination Therapies in Advanced Colorectal Cancer Patients.
Shares Oxaliplatin, Capecitabine and the tag pipeline.
- TrialA Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
Shares Leucovorin (folinic acid), Oxaliplatin and the tag pipeline.
- TrialA Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer
Shares Leucovorin (folinic acid), Oxaliplatin and the tag pipeline.
- TrialA Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy(PANKU-BTC01)
Shares Oxaliplatin, Capecitabine and the tag pipeline.
- TrialA Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Biliary Tract Cancer After Platinum-containing Chemotherapy Failure
Shares Oxaliplatin, Capecitabine and the tag pipeline.